一档有关生命、死亡与爱的播客,讲述生命科学及一切。

万物生长FM
Claim This Podcastby 万物生长FM
Podcast Overview
一档有关生命、死亡与爱的播客,讲述生命科学及一切。
Language
🇨🇳
Publishing Since
11/3/2022
1 verified contact email on file for 万物生长FM
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes

July 16, 2026
中国创新药2026半年复盘:政策底、业绩底、估值底 E.229
<p></p><img src="https://image.xyzcdn.net/lnxUsPW-1IoBBCsxD7tu116zIoz4.jpg"><p>2026年上半年,是创新药行业情绪、预期、基本面彻底撕裂、最具争议,也最关键的半年。从去年四季度开始的这一轮行情低迷,它和前几年纯粹的黑暗、纯粹的悲观完全不一样,我们能看到很多政策的利好,临床研究结果的利好,甚至是很多业绩的利好,但唯独看不到股价的上涨。大家很不理解,我也不理解。</p><p>抛开情绪不谈,回顾刚刚过去的半年,我最大的直观感受是:行业的悲观预期已经彻底出清,但结构性的问题依然顽固存在。好的一面是,所有压制行业的核心不确定性逐一落地,政策不再超预期收紧、企业基本面开始真实修复、市场估值风险充分释放;但不乐观的一面也很真实,内卷没有完全消失、中小企业生存压力仍在、很多管线依旧缺乏真实临床价值、出海和商业化的不确定性依然存在。</p><p>这一期复盘,我不是给大家灌输利好情绪,我想带大家客观看清,哪些是行业确定性的拐点机会,哪些是依然要规避的存量风险。我希望用政策、临床、业绩这三个维度做一个行业全景式的复盘,同时也会看一看行业重点的公司,过去半年的新变化。</p><p>希望这期内容对深耕行业、想看懂创新药真实逻辑的朋友有帮助。不管你是从业者、研究员还是投资人,听完这期,希望大家能跳出市场片面的情绪炒作,真正用长期、辩证的视角,看懂中国创新药底部复苏、格局分化的真相。</p><p><strong>内容时间轴:</strong></p><p><a class="timestamp">01:06</a> 为什么我认为创新药的政策底、业绩底、估值底已经确认</p><p><a class="timestamp">05:41</a> 政策的新周期的逻辑和新格局会怎样?</p><p><a class="timestamp">09:44</a> 为什么说2026年上半年值得关注的这几个政策是有逻辑的?</p><p><a class="timestamp">15:54</a> 从研发端看,这半年创新药行业有哪些新变化?</p><p><a class="timestamp">20:12</a> 为什么我坚定认为创新药BD不是一件负面的事?</p><p><a class="timestamp">22:12</a> 创新药的梯队该怎么划分?</p><p><a class="timestamp">25:05</a>百济神州</p><p><a class="timestamp">30:02</a> 恒瑞医药</p><p><a class="timestamp">33:41</a> 中国生物制药</p><p><a class="timestamp">35:53</a> 石药集团</p><p><a class="timestamp">37:49</a> 信达生物</p><p><a class="timestamp">40:11</a> 康方生物</p><p><a class="timestamp">43:13</a> 科伦博泰</p><p><a class="timestamp">44:49</a> 百利天恒</p><p><a class="timestamp">48:33</a> 晶泰科技</p><p><a class="timestamp">49:51</a> 英矽智能</p><p><a class="timestamp">51:32</a> 科济药业</p><p><a class="timestamp">53:13</a> 瑞博生物</p><p><a class="timestamp">54:37</a> 中国创新药行业值得拿出来和AI行业做对比</p><p>————————</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.xiaoyuzhoufm.com/podcast-topic/683d867038dcc57c642656c1">《中国创新药简史》专题</a></p><p>欢迎大家收听我和Jonathan的月度专题——<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.xiaoyuzhoufm.com/episode/6a3e1d3c2e335a35a809b51c">《<strong>药店vs电商,线上平台vs线下医疗机构,从《处方药网售指南》聊起|医业不设防E.224》</strong></a></p><figure><img src="https://image.xyzcdn.net/FtcbqitoWfWjE1i1_kWzWlMBnUaJ.png"></figure><p>听友群加VX:hooley777</p><p>商务合作:allthingsgrowing@qq.com</p><br><a href="https://oia.xiaoyuzhoufm.com/player/6a584d0f016dcc7e0542f3b9?openTranscript=true&utm_source=rss&as=cHQ9MTIyNjE5MjQ3JmN0PXJzcyZtdD04&autoOpen=false">在小宇宙查看该单集文稿</a>

July 13, 2026
超3亿人的“睡眠负债”该怎么破?ft.韩芳、李松蔚|下一个重磅E.228
<p></p><img src="https://image.xyzcdn.net/lnxUsPW-1IoBBCsxD7tu116zIoz4.jpg"><p>回头想想,好好睡一觉,好像成了当代人最奢侈的小事。<br><br>我们忙着上班、忙着焦虑、忙着治愈白天的疲惫,却唯独忽略了占据人生三分之一的睡眠。数据说超3亿中国人都背负着睡眠负债,我想我们每个人或多或少都有体会:入睡难、睡得浅、半夜易醒、睡醒依旧疲惫,长期的睡眠透支,悄悄拖垮了我们的状态、情绪和身体。</p><p>这一期节目,我和韩芳教授和李松蔚老师,从生理、病理、心理等多个角度,聊了聊大众最关心的几乎所有睡眠问题。希望可以对你有所帮助。</p><p><strong>本期嘉宾:</strong></p><p><strong>韩芳教授</strong>,北京大学人民医院睡眠医学科主任 <br><strong>李松蔚</strong>,知名心理健康博主</p><img src="https://image.xyzcdn.net/Fo366aJHmYpukQwQvhR4hkd9PA7z.png"><p>本期节目还有视频版,欢迎大家在微博搜索@新浪医药 或 @微博健康 观看 #下一个重磅# 视频版。</p><p><strong>【内容时间轴】</strong></p><p><a class="timestamp">05:03</a> 现代人睡眠问题增多的原因</p><p><a class="timestamp">13:06</a> 如何判断睡得好不好</p><p><a class="timestamp">15:46</a> 可穿戴睡眠监测设备可信吗</p><p><a class="timestamp">21:26</a> 睡眠的核心功能</p><p><a class="timestamp">25:31</a> 科学补觉与睡眠节律调节</p><p><a class="timestamp">31:00</a> 饮酒助眠?打鼾=睡得香?</p><p><a class="timestamp">38:48</a> 睡眠与情绪互为因果</p><p><a class="timestamp">42:48</a> 睡眠问题的临床解决方案</p><p><a class="timestamp">43:58</a> 不宁腿综合征、ADHD</p><p><a class="timestamp">55:30</a> 现代睡眠医学的发展</p><p>————————</p><p>欢迎大家收听我和Jonathan的月度专题——<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.xiaoyuzhoufm.com/episode/6a3e1d3c2e335a35a809b51c">《<strong>药店vs电商,线上平台vs线下医疗机构,从《处方药网售指南》聊起|医业不设防E.224》</strong></a></p><figure><img src="https://image.xyzcdn.net/FtcbqitoWfWjE1i1_kWzWlMBnUaJ.png"></figure><p>听友群加VX:hooley777</p><p>商务合作:allthingsgrowing@qq.com</p>

July 9, 2026
从高善文的病情自述,理解当下癌症治疗的逻辑E.227
<p></p><img src="https://image.xyzcdn.net/lnxUsPW-1IoBBCsxD7tu116zIoz4.jpg"><p>最近几天,相信很多朋友的朋友圈、社交平台,都被一条让人惋惜的消息刷屏了。著名经济学家高善文先生,因罹患外周T细胞淋巴瘤,不幸离世。</p><p>这两天我的朋友圈里,各种媒体的文章都在悼念他,我也经常看到他的那幅对联,上联“解释过去头头是道,似乎有理”,下联“预测未来躲躲闪闪,误差惊人”,横批“经济分析”。这副对联被认为体现了他对市场的敬畏、对研究的清醒,也成为其学术生涯的一个生动注脚。</p><p>而在他离世前,一个他在6月份跟人聊天的聊天记录,非常完整写了他从生病以来的<strong>完整病情自述</strong>。</p><p>这篇文字特别真诚、克制、条理清晰。整整一年多的求医路,从最初查不出病因的迷茫,到跨省跨地区辗转就医,从常规化疗、免疫治疗,再到最前沿的CAR-T细胞治疗、异体干细胞移植筹备,他把自己凶险的病情、每一步的治疗决策、医生的判断、各地区的医疗差异,事无巨细全部写了出来。</p><p>我个人认为对于疾病理解,特别是癌症的理解,这是一篇非常好的病情自述。不过不少人感受可能是,文字看得心里发酸,但<strong>看不太懂</strong>。满屏都是外周T细胞淋巴瘤、IV期癌症、PD-1抑制剂、炎症风暴、CAR-T、异体干细胞移植、临床试验……一堆专业名词扑面而来。</p><p>我们只直观感受到:这个病很凶、治疗很难、他拼尽了全力。但绝大多数人根本不明白:他到底得了什么病?为什么在北京十个月查不出问题?常规治疗为什么全部失效?最后尝试的前沿疗法,到底是什么原理?为什么说国内这项技术全球领先?</p><p>所以我觉得我有必要做期节目,抛开财经、抛开舆论,从癌症治疗的角度,复盘高善文先生一年半的抗癌历程。我尽量用让所有人都能听懂的方式,拆解他自述里所有的关键细节,试图让大家看懂这场普通人难以想象的、和癌症博弈的全过程,也读懂当下癌症治疗的真实现状。</p><p>内容时间轴:</p><p><a class="timestamp">03:31</a> 为什么听起来挺常见的淋巴瘤,却从北京到香港再到上海十个月才确诊?</p><p><a class="timestamp">08:19</a> 血管免疫母细胞T细胞淋巴瘤(AITL),凶险在哪里?</p><p><a class="timestamp">10:33</a> 手术、化疗、放疗、靶向药、免疫治疗、Car-T细胞疗法、干细胞移植,在癌症治疗什么阶段起作用?</p><p><a class="timestamp">17:36</a> 化疗之后体感好转,为何肿瘤没有控制住?</p><p><a class="timestamp">20:42</a> 为什么他化疗之后通过PET-CT检查出来了对化疗耐药</p><p><a class="timestamp">24:26</a> 为什么他说一些疗法和药物在香港没有获批,需要回京治疗</p><p><a class="timestamp">27:14</a> 什么是Car-T细胞疗法和异体干细胞移植,他最终选择的这套方案有何优势</p><p><a class="timestamp">31:10</a> Car-T细胞疗法桥接异体干细胞移植,这一套方案的费用大概是多少</p><p><a class="timestamp">33:31</a> 他为什么选择了参加临床试验项目,而不是直接用已经上市的Car-T?</p><p><a class="timestamp">36:33</a> 理解晚期癌症治疗的现状和无奈</p><img src="https://image.xyzcdn.net/Fm5_4DP_T_t3GK1MpTfIXh5MTkK_.jpg"><p>高善文的病情自述⬆️</p><p>节目中提到那期播客<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.xiaoyuzhoufm.com/episode/66611fde94977a26ef88fe7d"><strong>《E.61 当一个人查出癌症之后》</strong></a></p><p>欢迎大家收听我和Jonathan的月度专题——<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.xiaoyuzhoufm.com/episode/6a3e1d3c2e335a35a809b51c">《<strong>药店vs电商,线上平台vs线下医疗机构,从《处方药网售指南》聊起|医业不设防E.224》</strong></a></p><figure><img src="https://image.xyzcdn.net/FtcbqitoWfWjE1i1_kWzWlMBnUaJ.png"></figure><p>听友群加VX:hooley777</p><p>商务合作:allthingsgrowing@qq.com</p>
228 total episodes available
Similar Podcasts
Discover related shows you might enjoy
Deep-dive analytics for 万物生长FM
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is 万物生长FM?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 7 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.















